Man accused of stalking Caitlin Clark proclaims himself 'guilty as charged' in 1st court appearance
LA fires were larger and more intense because of planet-warming pollution, study suggests
Japan likely to miss primary budget surplus target for FY2025, sources say
No 97 Laura Siegemund upsets Olympic champion Zheng Qinwen at the Australian Open
Hotel policy change highlights struggles faced by unmarried couples looking for privacy in India
Oil little changed as falling US stockpiles outweigh soft demand outlook
Tiger Woods makes indoor golf debut and finds humor in blowout loss, noting 'how bad pros can be'
(Reuters) -Mayne Pharma has filed a lawsuit against India's Sun Pharma over infringements of patents related to a certain product used for menopause-related vaginal pain, the Australian drugmaker said on Thursday.
In the lawsuit filed at the United States District Court for New Jersey, Mayne Pharma accused its rival of violating all 20 Orange Book-listed patents linked to IMVEXXY - a vaginal insert aimed at reducing pain during sexual intercourse after menopause.
Orange Book-listed patents are those approved by the U.S. Food and Drug Administration (FDA) and deemed safe to use.
The Australian drugmaker said it filed the lawsuit after a notification indicated Sun Pharma's submission of an Abbreviated New Drug Application (ANDA) to the FDA seeking approval to market a generic version of IMVEXXY.
The ANDA is a request filed to the health regulator for approval of an already licensed drug to manufacture the medication in the United States. These application processes do not warrant the applicant to go through a clinical trial.
Sun Pharma did not immediately respond to a Reuters' request for comment.
Mayne Pharma's complaint also indicated that Sun Pharma filed a Paragraph IV certification, suggesting the latter challenged the patent's (IMVEXXY) listing in the Orange Book as invalid or inapplicable.
This "formally initiates the litigation process under the Hatch-Waxman Act and triggers a 30-month stay of any potential FDA approval for Sun Pharma's ANDA," Mayne Pharma said in a statement.
IMVEXXY is distributed by TherapeuticsMD and had sealed the FDA's approval in 2018.
(Reporting by Rajasik Mukherjee; Editing by Sherry Jacob-Phillips)
